|
private:mimivax
|
9310747
|
May 30th, 2019 12:00AM
|
MimiVax, LLC
|
100
|
2.00
|
Open
|
Pharmaceuticals
|
May 29th, 2019 08:18PM
|
May 29th, 2019 08:18PM
|
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates
MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer.
SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2 clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) as well as Phase 1 in Neuro-Endocrine Tumors (NET)
|
Open
|
Immunotherapy, Vaccines, Oncology, Pharmaceutical Developement
|
Open
|
Elm & Carlton Streets
|
Buffalo
|
NY
|
US
|
14263
|
|
MimiVax
|
|
Health Care Equipment & Services
|
|
private:mimivax
|
9310747
|
Mar 23rd, 2018 12:00AM
|
MimiVax, LLC
|
63
|
2.00
|
Open
|
Pharmaceuticals
|
Mar 23rd, 2017 10:51AM
|
Mar 23rd, 2017 10:51AM
|
MimiVax's lead agent, SurVaxM, has recently completed its "first-in-man" clinical trial with strongly encouraging results. “A Phase I Study of Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Malignant Gliomas.”
A phase I study in multiple myeloma, "Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy" is scheduled to open in March 2015.
The phase II study in malignant glioma, "Safety and Efficacy of SurVaxM in Survivin-Positive Newly Diagnosed Glioblastoma" is being prepared for opening as a multicenter clinical trial to open in 2015.
MimiVax was formed to commercialize intellectual property developed at Roswell Park Cancer Institute (RPCI). We are developing immunotherapeutic vaccines and targeted therapies for cancer treatment. SurVaxM is the lead agent in our drug pipeline. This is a unique cancer vaccine that stimulates a potent immune response targeted to the survivin molecule, an important cellular protein thought to sustain the viability of many types of tumor cells. Studies of the vaccine have shown that it substantially prolongs survival in animals with brain, ovarian, renal, melanoma and prostate cancers. MimiVax is performing pre-clinical laboratory studies and human clinical trials in order to propel more effective immunological cancer therapies into the clinic.
|
|
|
|
|
|
|
|
|
|
MimiVax
|
|
Health Care Equipment & Services
|
|
private:mimivax
|
9310747
|
Feb 17th, 2018 12:00AM
|
MimiVax, LLC
|
63
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
MimiVax's lead agent, SurVaxM, has recently completed its "first-in-man" clinical trial with strongly encouraging results. “A Phase I Study of Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Malignant Gliomas.”
A phase I study in multiple myeloma, "Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy" is scheduled to open in March 2015.
The phase II study in malignant glioma, "Safety and Efficacy of SurVaxM in Survivin-Positive Newly Diagnosed Glioblastoma" is being prepared for opening as a multicenter clinical trial to open in 2015.
MimiVax was formed to commercialize intellectual property developed at Roswell Park Cancer Institute (RPCI). We are developing immunotherapeutic vaccines and targeted therapies for cancer treatment. SurVaxM is the lead agent in our drug pipeline. This is a unique cancer vaccine that stimulates a potent immune response targeted to the survivin molecule, an important cellular protein thought to sustain the viability of many types of tumor cells. Studies of the vaccine have shown that it substantially prolongs survival in animals with brain, ovarian, renal, melanoma and prostate cancers. MimiVax is performing pre-clinical laboratory studies and human clinical trials in order to propel more effective immunological cancer therapies into the clinic.
|
|
|
|
|
|
|
|
|
|
MimiVax
|
|
Health Care Equipment & Services
|
|
private:mimivax
|
9310747
|
Feb 16th, 2018 12:00AM
|
MimiVax, LLC
|
63
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
MimiVax's lead agent, SurVaxM, has recently completed its "first-in-man" clinical trial with strongly encouraging results. “A Phase I Study of Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Malignant Gliomas.”
A phase I study in multiple myeloma, "Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy" is scheduled to open in March 2015.
The phase II study in malignant glioma, "Safety and Efficacy of SurVaxM in Survivin-Positive Newly Diagnosed Glioblastoma" is being prepared for opening as a multicenter clinical trial to open in 2015.
MimiVax was formed to commercialize intellectual property developed at Roswell Park Cancer Institute (RPCI). We are developing immunotherapeutic vaccines and targeted therapies for cancer treatment. SurVaxM is the lead agent in our drug pipeline. This is a unique cancer vaccine that stimulates a potent immune response targeted to the survivin molecule, an important cellular protein thought to sustain the viability of many types of tumor cells. Studies of the vaccine have shown that it substantially prolongs survival in animals with brain, ovarian, renal, melanoma and prostate cancers. MimiVax is performing pre-clinical laboratory studies and human clinical trials in order to propel more effective immunological cancer therapies into the clinic.
|
|
|
|
|
|
|
|
|
|
MimiVax
|
|
Health Care Equipment & Services
|
|
private:mimivax
|
9310747
|
Feb 15th, 2018 12:00AM
|
MimiVax, LLC
|
63
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
MimiVax's lead agent, SurVaxM, has recently completed its "first-in-man" clinical trial with strongly encouraging results. “A Phase I Study of Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Malignant Gliomas.”
A phase I study in multiple myeloma, "Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy" is scheduled to open in March 2015.
The phase II study in malignant glioma, "Safety and Efficacy of SurVaxM in Survivin-Positive Newly Diagnosed Glioblastoma" is being prepared for opening as a multicenter clinical trial to open in 2015.
MimiVax was formed to commercialize intellectual property developed at Roswell Park Cancer Institute (RPCI). We are developing immunotherapeutic vaccines and targeted therapies for cancer treatment. SurVaxM is the lead agent in our drug pipeline. This is a unique cancer vaccine that stimulates a potent immune response targeted to the survivin molecule, an important cellular protein thought to sustain the viability of many types of tumor cells. Studies of the vaccine have shown that it substantially prolongs survival in animals with brain, ovarian, renal, melanoma and prostate cancers. MimiVax is performing pre-clinical laboratory studies and human clinical trials in order to propel more effective immunological cancer therapies into the clinic.
|
|
|
|
|
|
|
|
|
|
MimiVax
|
|
Health Care Equipment & Services
|
|
private:mimivax
|
9310747
|
Feb 14th, 2018 12:00AM
|
MimiVax, LLC
|
63
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
MimiVax's lead agent, SurVaxM, has recently completed its "first-in-man" clinical trial with strongly encouraging results. “A Phase I Study of Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Malignant Gliomas.”
A phase I study in multiple myeloma, "Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy" is scheduled to open in March 2015.
The phase II study in malignant glioma, "Safety and Efficacy of SurVaxM in Survivin-Positive Newly Diagnosed Glioblastoma" is being prepared for opening as a multicenter clinical trial to open in 2015.
MimiVax was formed to commercialize intellectual property developed at Roswell Park Cancer Institute (RPCI). We are developing immunotherapeutic vaccines and targeted therapies for cancer treatment. SurVaxM is the lead agent in our drug pipeline. This is a unique cancer vaccine that stimulates a potent immune response targeted to the survivin molecule, an important cellular protein thought to sustain the viability of many types of tumor cells. Studies of the vaccine have shown that it substantially prolongs survival in animals with brain, ovarian, renal, melanoma and prostate cancers. MimiVax is performing pre-clinical laboratory studies and human clinical trials in order to propel more effective immunological cancer therapies into the clinic.
|
|
|
|
|
|
|
|
|
|
MimiVax
|
|
Health Care Equipment & Services
|
|
private:mimivax
|
9310747
|
Feb 13th, 2018 12:00AM
|
MimiVax, LLC
|
63
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
MimiVax's lead agent, SurVaxM, has recently completed its "first-in-man" clinical trial with strongly encouraging results. “A Phase I Study of Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Malignant Gliomas.”
A phase I study in multiple myeloma, "Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy" is scheduled to open in March 2015.
The phase II study in malignant glioma, "Safety and Efficacy of SurVaxM in Survivin-Positive Newly Diagnosed Glioblastoma" is being prepared for opening as a multicenter clinical trial to open in 2015.
MimiVax was formed to commercialize intellectual property developed at Roswell Park Cancer Institute (RPCI). We are developing immunotherapeutic vaccines and targeted therapies for cancer treatment. SurVaxM is the lead agent in our drug pipeline. This is a unique cancer vaccine that stimulates a potent immune response targeted to the survivin molecule, an important cellular protein thought to sustain the viability of many types of tumor cells. Studies of the vaccine have shown that it substantially prolongs survival in animals with brain, ovarian, renal, melanoma and prostate cancers. MimiVax is performing pre-clinical laboratory studies and human clinical trials in order to propel more effective immunological cancer therapies into the clinic.
|
|
|
|
|
|
|
|
|
|
MimiVax
|
|
Health Care Equipment & Services
|
|
private:mimivax
|
9310747
|
Feb 12th, 2018 12:00AM
|
MimiVax, LLC
|
63
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
MimiVax's lead agent, SurVaxM, has recently completed its "first-in-man" clinical trial with strongly encouraging results. “A Phase I Study of Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Malignant Gliomas.”
A phase I study in multiple myeloma, "Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy" is scheduled to open in March 2015.
The phase II study in malignant glioma, "Safety and Efficacy of SurVaxM in Survivin-Positive Newly Diagnosed Glioblastoma" is being prepared for opening as a multicenter clinical trial to open in 2015.
MimiVax was formed to commercialize intellectual property developed at Roswell Park Cancer Institute (RPCI). We are developing immunotherapeutic vaccines and targeted therapies for cancer treatment. SurVaxM is the lead agent in our drug pipeline. This is a unique cancer vaccine that stimulates a potent immune response targeted to the survivin molecule, an important cellular protein thought to sustain the viability of many types of tumor cells. Studies of the vaccine have shown that it substantially prolongs survival in animals with brain, ovarian, renal, melanoma and prostate cancers. MimiVax is performing pre-clinical laboratory studies and human clinical trials in order to propel more effective immunological cancer therapies into the clinic.
|
|
|
|
|
|
|
|
|
|
MimiVax
|
|
Health Care Equipment & Services
|
|
private:mimivax
|
9310747
|
Feb 11th, 2018 12:00AM
|
MimiVax, LLC
|
63
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
MimiVax's lead agent, SurVaxM, has recently completed its "first-in-man" clinical trial with strongly encouraging results. “A Phase I Study of Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Malignant Gliomas.”
A phase I study in multiple myeloma, "Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy" is scheduled to open in March 2015.
The phase II study in malignant glioma, "Safety and Efficacy of SurVaxM in Survivin-Positive Newly Diagnosed Glioblastoma" is being prepared for opening as a multicenter clinical trial to open in 2015.
MimiVax was formed to commercialize intellectual property developed at Roswell Park Cancer Institute (RPCI). We are developing immunotherapeutic vaccines and targeted therapies for cancer treatment. SurVaxM is the lead agent in our drug pipeline. This is a unique cancer vaccine that stimulates a potent immune response targeted to the survivin molecule, an important cellular protein thought to sustain the viability of many types of tumor cells. Studies of the vaccine have shown that it substantially prolongs survival in animals with brain, ovarian, renal, melanoma and prostate cancers. MimiVax is performing pre-clinical laboratory studies and human clinical trials in order to propel more effective immunological cancer therapies into the clinic.
|
|
|
|
|
|
|
|
|
|
MimiVax
|
|
Health Care Equipment & Services
|
|
private:mimivax
|
9310747
|
Feb 10th, 2018 12:00AM
|
MimiVax, LLC
|
63
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
MimiVax's lead agent, SurVaxM, has recently completed its "first-in-man" clinical trial with strongly encouraging results. “A Phase I Study of Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Malignant Gliomas.”
A phase I study in multiple myeloma, "Safety, Tolerability and Immunological Effects of SurVaxM in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy" is scheduled to open in March 2015.
The phase II study in malignant glioma, "Safety and Efficacy of SurVaxM in Survivin-Positive Newly Diagnosed Glioblastoma" is being prepared for opening as a multicenter clinical trial to open in 2015.
MimiVax was formed to commercialize intellectual property developed at Roswell Park Cancer Institute (RPCI). We are developing immunotherapeutic vaccines and targeted therapies for cancer treatment. SurVaxM is the lead agent in our drug pipeline. This is a unique cancer vaccine that stimulates a potent immune response targeted to the survivin molecule, an important cellular protein thought to sustain the viability of many types of tumor cells. Studies of the vaccine have shown that it substantially prolongs survival in animals with brain, ovarian, renal, melanoma and prostate cancers. MimiVax is performing pre-clinical laboratory studies and human clinical trials in order to propel more effective immunological cancer therapies into the clinic.
|
|
|
|
|
|
|
|
|
|
MimiVax
|
|
Health Care Equipment & Services
|